Alternative Antiseizure Medication for Perampanel-Induced Bradycardia
If perampanel causes bradycardia, switch to levetiracetam as the first-line alternative, as it has no cardiac effects and does not cause bradycardia or conduction abnormalities.
Rationale for Levetiracetam
Levetiracetam is the optimal replacement because:
- No cardiac effects: Unlike perampanel, levetiracetam does not affect heart rate, conduction, or blood pressure 1
- Broad efficacy: Effective for both focal-onset and generalized seizures, matching perampanel's indications 2
- Favorable pharmacokinetics: No significant drug interactions, renal elimination, and predictable dosing 2
- Well-tolerated: Minimal CNS side effects compared to perampanel's known behavioral and sedative effects 1, 3
Dosing Strategy
Start levetiracetam at 500 mg twice daily, titrating by 500 mg increments every 1-2 weeks to a target of 1,000-1,500 mg twice daily (maximum 3,000 mg/day total). This allows gradual transition while discontinuing perampanel 2.
Alternative Second-Line Options
If levetiracetam is contraindicated or ineffective:
For Focal Seizures:
- Lacosamide: 100-200 mg twice daily (avoid if bradycardia is due to AV nodal dysfunction, as lacosamide can prolong PR interval) 2
- Lamotrigine: Start 25 mg daily, slow titration over 6-8 weeks to 200-400 mg/day (delayed onset but excellent tolerability) 2
- Zonisamide: 100-400 mg daily (carbonic anhydrase inhibitor, generally cardiac-neutral) 2
For Generalized Tonic-Clonic Seizures:
- Valproate: 500-1,000 mg twice daily (effective but monitor for hepatotoxicity, teratogenicity in women of childbearing potential) 4, 2
- Lamotrigine: Same dosing as above 2
Critical Considerations
Avoid these medications in patients with bradycardia:
- Beta-blockers (metoprolol, propranolol, esmolol): Directly worsen bradycardia through AV nodal blockade 5, 6
- Calcium channel blockers (diltiazem, verapamil): Cause bradycardia and AV conduction delays 5, 6
- Phenobarbital: Can exacerbate bradycardia, particularly in patients with pre-existing sinus or AV node dysfunction 7, 3
Important caveat: While phenobarbital was used in one pediatric perampanel overdose case to increase metabolism 3, this was for acute toxicity management, not chronic therapy. Phenobarbital itself carries bradycardia risk and should not be used as a routine alternative 7.
Transition Protocol
- Assess bradycardia severity: If symptomatic (dizziness, syncope, hypotension) or heart rate <50 bpm, discontinue perampanel immediately 8, 9
- Initiate levetiracetam: Start at therapeutic dose (500 mg BID) given its rapid onset and lack of titration requirement for safety
- Taper perampanel: Given its 105-hour half-life 3, effects will persist for weeks. Reduce by 2 mg every 1-2 weeks while monitoring seizure control
- Monitor cardiac status: Repeat ECG and heart rate assessment 1-2 weeks after perampanel discontinuation to confirm resolution 8, 9
When Bradycardia Persists
If bradycardia continues despite stopping perampanel, consider:
- Reversible causes: Hypothyroidism, electrolyte abnormalities, other medications (digoxin, amiodarone) 9
- Permanent pacing: Only if symptomatic bradycardia persists and is not medication-related, following standard indications for sinus node dysfunction 8, 9
The key principle: Perampanel-induced bradycardia is a reversible, drug-related phenomenon 1. Switching to a cardiac-neutral antiseizure medication like levetiracetam resolves the issue while maintaining seizure control.